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difference between the vigorous physical activity (VPA) carried out by men and 
women as on average men carry out 37.73 minutes more VPA compared to women 
(meanF= 77.97, meanM= 40.24 min/week, p< 0.001). According to the age groups the 
VPA level of women after the age of 40 showed stability on a lower level while the 
reduction of VPA of men is continuous until the age of 60 when gender gap of VPA 
disappears (p< 0.001). ConClusions: Regarding gender differences, women were 
less active than men in PA, carrying out significantly less vigorous PA. The results 
of the observational research confirmed the need for a well-aimed intervention to 
emphasize PA among women.
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Tailoring SPonSor-Payer engagemenT To FaciliTaTe eFFecTive and 
Fair PaTienT acceSS
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objeCtives: To understand how best to facilitate effective, early dialogue between 
pharma and payers by determining payer needs and drivers, facilitating sponsor 
alignment of market access strategies to meet those needs, and ultimately ensuring 
patient access to innovative and effective treatments. Methods: Questionnaires 
were sent to 5 pharmaceutical companies to determine their payer engagement 
strategies, whilst individual interviews were conducted with 5 payer proxies (Spain, 
Italy, France, UK, Germany) to gather their feedback on current payer engagement 
practices and suggestions for future working practices with pharma. A decision tree 
was then constructed to provide a framework detailing the optimal engagement 
format for specific time points in the product lifecycle, which was subsequently veri-
fied by all participants to substantiate its utility in meeting the needs of both par-
ties. Results: Sponsors favoured face-to-face ‘advisory board’ meetings for payer 
engagement, whilst payer interviewees cited a neutral reaction towards this type of 
engagement, preferring more dynamic engagement activities closely tailored to both 
the individual issue at hand and their own objectives. Additional payer emphasis 
was placed on the need for early engagement and incorporation of key variables into 
clinical trial outcomes. Finally, feedback from both samples suggested an ‘advisory 
board’ structure for engagement is not always efficient or effective, prompting us 
to develop a framework detailing alternative engagement options aligned to key 
research questions. Both groups responded positively to the model: sponsors citing 
efficiency and payers an appreciation of the range of ways sponsors were prepared 
to engage. However, some payers cited a hesitancy toward more virtual methods 
and their ability to facilitate effective two-way dialogue. ConClusions: Payers 
are open to and supportive of alternative modes of engagement with sponsors to 
promote more effective, early collaboration whereby each parties’ needs, drivers 
and constraints can be understood to ultimately ensure mutual benefit and fair 
and appropriate patient access.
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objeCtives: Stress appears during the nursing education, that may have nega-
tive effect on their performance at school and their psychologocal and physical 
well-being. The aim of the present study was to investigate the clinical practice 
due to effects based on the mood and physiological parameters among the first 
students starting their clinical practice and the exercise several times, moving 
students in a clinical setting. Methods: ABPM device in systolic and diastolic 
blood pressure, heart rate and mean arterial blood pressure. In the present pilot 
study also measured through 9 days of 30 -minute measurements, the first day of 
the adaptation period. 23 people II. and III. years of nursing students participated 
voluntarily in the study. Each student filled out a questionnaire compiled for which 
demographic data scheme, consumer protection, health assess exercise asked for 
it. The mood of the Brunel Mood Scale was used to assess which 32 questions, in 
which the negative value means a better mood. An analysis of variance, Student’s t 
test, Mann-Withny test was IBM SPSS 20.0 program (p< 0,05). Students averaged daily 
parameters was carried out calculations. Results: The results show that each of 
the II. group (p< 0,05), and III. group (p= 0,041) between test days was just the mood 
worth experiencing significant difference with regard to the physiological param-
eters that did not materialize.Testing two-sample t-test we looked for significant 
differences in the II. grade average value and III. the annual average values. Only 
significant differences were obtained for heart rate (p= 0,05). ConClusions: In case 
of this sample physiological parameters does not fully reflect the mood changes 
during clinical practice. Further, at least 30 days (one month) follow-up studies and 
the increase of the number of elements are needed to show the physical changes 
in stress and physiological parameters between groups.
HealTH care uSe & Policy STudieS – Health Technology assessment  
Programs
PHP240
are medicineS granTed wiTH a condiTional aPProval by THe 
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objeCtives: In 2004, the European Medicines Agency (EMA) was granted the ability 
to authorise medicines under a conditional approval (CA) status.1 This status aims 
at accelerating patients’ access to medicines when they are intended for use in 
seriously debilitating and/or life-threatening diseases, in response to public health 
threats, or designated as orphan medicines, despite incomplete data. These medi-
cines must be evaluated by Health Technology Assessment (HTA) bodies before being 
A&F reports more carefully or frequently that the specialists. ConClusions: 
Physicians believed that revising the feedback report’s format and content could 
increase its effectiveness. Taking physicians’ opinions into consideration, the 
researcher concludes that A&F forms have some shortcomings, e.g. the reports do 
not cover all prescriptions of physicians, do not take into account the patients case-
mix, and might be limited via comparing physicians with non-comparable peers. 
Appropriately designed PEMs might be an effective strategy to improve prescribing, 
and their use should be widened.
PHP235
TrendS in HoSPiTal STandardized morTaliTy raTioS in JaPan
Shinjo D1, Fushimi K2
1The University of Tokyo Hospital, Tokyo, Japan, 2Tokyo Medical and Dental University Graduate 
School of Medicine, bunkyo-ku, Japan
objeCtives: The hospital standardized mortality ratio (HSMR) is an indicator that 
adjusts hospital mortality for case-mix differences. HSMR is controversial, but 
used as a hospital performance measure. However, trends for the ratio (especially 
according to degree of severity) have not yet been well analyzed. Methods: A 
total of 3 647 693 admissions from 266 hospitals were extracted from a Japanese 
administrative database (patients between 2008 and 2012, from July to December). 
We estimated the probability of in-hospital death by fitting a logistic regression 
model. In each year, HSMRs were obtained by calculating the ratio of the num-
ber of observed deaths to the number of expected deaths, and the trend of the 
HSMR was analyzed. The HSMR trends in each comorbidity group, defined by the 
Charlson comorbidity index, were analyzed as well. Results: The c-index value 
was 0.871 for the HSMR model, and its value each year was stable and fairly high 
(lowest c-index 0.866 and highest c-index 0.877). The HSMR followed a constant 
decreasing trend over time; it fell by 18.7% from 110.4 in 2008 to 91.7 in 2012. The 
reduction in HSMR was not present in the severe comorbidity group, while the 
decreasing trend was observed in the mild comorbidity group. ConClusions: 
Our model demonstrated excellent discrimination without detailed clinical data, 
enabling us to analyze HSMR trends. The downtrend of the HSMR may be partly 
because of improvements in quality of care, changes in hospital behavours based 
on policy inducement, and other factors. Given the challenges in assessing qual-
ity of hospital care, more effort is needed to achieve appropriate evaluation of 
hospital performance.
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objeCtives: An increasing motivation can be experienced among professional 
workers within Hungarian healthcare system towards foreign employment or 
career change. Our goal was to assess Hungarian physiotherapists’ migration and 
career changing behaviour and understand the underlying factors. Methods: 
We made a national survey in Hungary during a period of five months (from April 
to August, 2014). The questionnaire was sent to the members of the Hungarian 
Physiotherapists’ Association, attached to the monthly newsletter in online form. 
We received 215 reply out of the sent 340 questionnaire, the response rate was 
63.23 %. For data collection the Effort-Reward Imbalance validated questionnaire 
and our own questionnaire were used in online form. Only physiotherapists who 
practice in Hungary were included. The data were analyzed by SPSS 20.0 statis-
tics software. The significance limit was p< 0.05. Results: Our results suggest 
that age (p< 0.05) and the rate of financial appreciation experienced in the work-
place (p< 0.01) significantly affects the appearance of migratory thoughts. Those 
physiotherapists who do not feel themselves financially appreciated 55 times 
more likely to search for employment outside the country’s borders [OR= 55.28, 
CI (95%)= 18.85 to 161.12]. 50,6% of the subjects involved in the study are con-
sidering to leave the physiotherapist career (n= 109), the most common causes 
for that are unfavourable financial-and moral recognition and the lack of pos-
sibilities career advancement (p< 0.01), (p< 0.001), (p< 0.001). ConClusions: 
In order to prevent our already highly-qualified colleagues from leaving the 
country or from considering to leave the profession we should concentrate on 
increasing the financial and moral appreciation of the profession within the 
Hungarian healthcare system and also to provide better opportunities for career 
advancement.
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objeCtives: Low energy balance is the consequence of decrease physical activ-
ity (PA), sedentary lifestyle, and inappropriate dietary habits in modern societies, 
while the most important indicator of energy transmission is PA. Several research 
point out the gender-related differences in PA where data on women are worse: 
they do sports less and choose less physical activity in their free-time than men. 
The aim of our research was to map the Hungarian adult’s vigorous physical activ-
ity examining gender differences. Methods: Data were collected in Summer 
2014. The representative (by age & gender) sample consisted of 1059 adults. The 
research was carried out in two Hungarian counties, Baranya and Zala. We devel-
oped a tablet-based survey to examine PA. Using the IPAQ long questionnaire, we 
examined nutrition habits by the Food Frequency Questionnaire; and gathered 
anthropometric data with body composition monitors. Data analysis was carried 
out by SPSS 22.0 for Windows. Results: The sample size of adult participants was 
1059 (female(F)= 53.1%, male(M)= 46.9%), their mean age was 48±17.54 years. The 
self-rated health index of the low PA group of the adults is significantly lower than 
medium of high PA groups, especially for women (p= 0,024). We found significant 
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requirement in France; continuous monitoring will be needed to better understand 
positive and negative drivers of decisions.
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objeCtives: This study was designed to understand consumer interest in a mobile 
application designed to allow individuals to view their personal health record on a 
mobile device, and to share their health records with someone else if they choose. 
As a secondary objective, this study evaluated the likelihood of consumers to use 
the device based on the varying risk of a leak of their identifiable information (risk 
tolerance). Methods: A representative (U.S.) sample of 1,000 adults completed 
an online survey about their interest in an EHR mobile application. Interest in the 
application was elucidating using a 7-point Likert scale and a standard gamble 
(SG) exercise. Results: Prior to any indication of a potential privacy risk, 31% of 
consumers indicate they would be very likely to download an EHR mobile applica-
tion (rated 6 or 7 on 7-point Likert scale; 4.0 mean). Nearly half (44%) of those who 
do not expect to use the app indicate they have privacy concerns. Based on the SG, 
only 50% report they would download the mobile application if there was a 95% 
chance their data was completely secure. Expected use of the application declines 
rapidly; 39% would use it if there was a 90% chance their data was completely 
secure and 31% would use it if there was an 85% chance their data was completely 
secure. Only 3% are still interested in the application with only a 5% chance their 
data was completely secure. ConClusions: There is a sizeable market for EHR 
mobile applications. Up to half of consumers report interest in using an EHR mobile 
application; and yet, there are important data concerns. Particularly given large-
scale data breaches of large organizations, it will be critical for developers to quell 
fears of potential users of a data leak.
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objeCtives: Since January 2011, the German G-BA has evaluated new drugs on 
their degree of added benefit versus a comparator therapy. We used disease-specific 
Disability Adjusted Life Years (DALYs), reported by the World Health Organization 
(WHO) as the sum of Years of Life Lost from mortality (YLL) plus Years Lost due to 
Disability (YLD), to help explain G-BA benefit assessment decisions. Methods: 
EMA-approved drugs (January 2010-June 2015) were identified from European Public 
Assessment Reports (EPARs) and cross-referenced with the G-BA website to create 
an analysis set of drugs that have received benefit assessment ratings. Drugs with 
EMA orphan-drug designation were excluded. We defined Added Benefit (AB) as 
drugs that received G-BA ratings of “considerable”, “low”, or “unquantifiable” ben-
efit in any patient subgroup, and No Added Benefit (NAB) as drugs only receiving 
ratings of “no additional benefit” and “inferior”. Using WHO-reported German 2012 
DALYs, proportions of YLLs and YLDs for each drug’s lead indication were calculated: 
Drugs for diseases in which YLLs > 75% of the DALY were defined as High Mortality 
Drugs (HMD); drugs for all other diseases were Low Mortality Drugs (LMD). We then 
predicted the odds of receiving AB versus NAB based on this new metric. SPSS was 
used to perform Fisher’s exact test and to generate Odds Ratios (OR). Sensitivity 
analyses were performed on the %YLL threshold definition. Results: From 373 
EPARs, we identified 73 non-orphan drugs receiving G-BA benefit assessment rat-
ings, 58 of which had matched DALY data for the lead indication. Of these 58 drugs, 
35 were indicated for HMDs while 23 had LMD indications. 30 of 35 (86%) HMDs 
received an AB rating while only 4 of 23 (17%) LMDs received an AB rating (p< 0.001, 
OR: 28.6). ConClusions: Our analysis suggests that in Germany there may be a 
demonstrated and predictable bias for drugs for fatal diseases.
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objeCtives: To assess the progress of a large group of innovative drugs evaluated 
recently under the HTA system introduced in Romania in 2014, which is the mecha-
nism now used to reach decisions on which new medicines are included on the 
reimbursement list. Methods: A systematic study of the HTA decisions already 
taken by the department for health technology assessment of the Romanian drug 
agency was undertaken, to ascertain the number of medicines / indications approved 
for unconditional reimbursement (not requiring cost-volume contracts), conditional 
reimbursement (requiring cost-volume contracts) and those not qualifying for reim-
bursement. Patterns were sought and identified among those drugs / indications 
which are awarded higher and lower points scores. Results: Of the 144 HTA deci-
sions, considering only originator medicines and their indications, there have been 23 
recommendations for unconditional reimbursement, 51 recommendations for condi-
tional reimbursement, and 70 recommendations for exclusion from reimbursement. 
Among the therapeutic areas and drug types in which unconditional reimbursement 
decisions are frequent are new oral anticoagulant drugs and type-2 diabetes drugs. 
Many older originator medicines have tended to receive lower points scores, not quali-
fying for reimbursement. ConClusions: The HTA points system in Romania is in its 
early stages but already some patterns are emerging from the combination of criteria 
used to accumulate points – including decisions by western European HTA bodies, 
the number of EU member states in which a drug is reimbursed, and the impact on 
the budget of the Romanian health insurer. With major legislative transformations 
underway in Romania’s pharmaceutical pricing and reimbursement system, the real 
made available to patients. The objective of this abstract is to highlight the difference 
of data requirements between the EMA and some of the main HTA bodies, and the 
subsequent outcomes in terms of access and reimbursement decisions. Methods: 
The list of medicines under CA status was downloaded on March 16th 2015 from the 
EMA website.2 For each medicine, advice from the National Institute for Health and 
Care Excellence (NICE), Scottish Medicines Consortium (SMC), National Authority 
for Health (HAS) and Federal Joint Committee (GBA) was taken from the agencies’ 
websites.3 The HTA outcomes were measured from final recommendation in the 
UK, the medical benefit (SMR) and improvement in medical benefit (ASMR) scores 
in France and the level of additional benefit in Germany. Medicines approved 
after March 2014 (n = 3) and vaccines (n = 2) were excluded. Results: 77% of the 
selected medicines had at least one unfavourable HTA outcome (defined as no or 
restricted recommendation in the UK, SMR lower than substantial and/or ASMR V 
in France, no or unquantifiable additional benefit in Germany). 50% had a majority 
of unfavourable HTA outcomes. ConClusions: Although the EMA seems to have 
accelerated patient access to selected medicines, it does not actually translate into 
patient accessibility as regulators and payers have a different perception on the 
benefits these medicines offer. Greater alignment between regulators and payers is 
needed for patients. 1Article 14(7) of Regulation (EC) No 726/2004; 2http://www.ema.
europa.eu/ema/; 3http://www.has-sante.fr/portail/jcms/r_1500918/en/les-avis-sur-
les-medicaments, http://www.english.g-ba.de/, https://www.nice.org.uk/, https://
www.scottishmedicines.org.uk/Home
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objeCtives: Hospitals need a formalized system to introduce new health tech-
nologies. Hospital-based HTA (HB-HTA) units can provide relevant and timely 
information to decision makers. However, to date no comprehensive body of 
knowledge of current practices and tools exists to guide how to set up these units 
in hospitals. AdHopHTA, a European research project funded by the FP7, aims to 
gather information and knowledge and develop these tools. Therefore, our objec-
tives are to present the handbook and web-based toolkit for HB-HTA developed 
by the AdHopHTA project, which aims to guide and facilitate the setting-up and 
the daily work (e.g. assessments) of an HB-HTA unit. Methods: AdHopHTA has 
used a multi-method approach to develop the content of the handbook and toolkit 
including 6 literature reviews, 107 face-to-face surveys, 40 case studies, 1 large-
scale survey, 1 focus group, 1 Delphi process, 1 validation workshop and several 
Steering and Advisory Committee meetings. In total 375 people from 20 differ-
ent countries have provided their input. Results: The handbook presents the 
informational needs and organizational models of HB-HTA units in Europe. It also 
describes the positive impact of HB-HTA in the adoption of new health technolo-
gies in hospitals and how to create a comprehensive HTA ecosystem through the 
interaction between national or regional HTA organizations and HB-HTA units. 15 
guiding principles for good practices in HB-HTA are also presented using current 
examples from existing HB-HTA units. The Toolkit is built based on these guiding 
principles. It consists of practical guidance grouped into four dimensions (the 
assessment process; leadership, strategy and partnerships; resources and and 
impact). It includes proposed solutions to potential problems as well as specific 
tools (e.g. AdHopHTA mini-HTA template) for each dimension. ConClusions: 
The AdHopHTA Handbook and Toolkit are support instruments for designing, 
setting-up and running HB-HTA units.
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objeCtives: The Commission for Economic Evaluations and Public Health 
(Commission Evaluation Economique et de Santé Publique, (CEESP)) has been con-
ducting health economic evaluations since 2008. Due to continued economic pressure, 
as of October 2013, manufacturers are required to submit an economic evaluation to 
the CEESP under certain conditions, in addition to the Commission de Transparence’s 
existing clinical assessment. The objective of this analysis was to gain a better under-
standing of the drivers of positive and negative CEESP decisions. Methods: All publi-
cally available CEESP decisions were retrieved from the agency’s website in April 2015. 
The CEESP evaluates submissions against the HAS’ pharmacoeconomic guidelines, in 
which areas of weakness are identified through a system of “reserves” rather than a 
strict ICER threshold. Data was extracted to determine the number of and rationale 
for minor, important, and major reserves awarded by CEESP to the manufacturer’s 
submission, as well as accepted incremental cost-effectiveness ratios. Results: 
According to HAS’s methodological guide for economic evaluations, cost-effectiveness 
should be considered alongside clinical efficacy. At the time of analysis, four CEEPS 
appraisals were publically available. 50% of submissions had ICERs above 100,000 EUR 
per QALY gained, and based on findings to date, no firm ICER threshold was apparent. 
50% of submissions were found to have minor, important, as well as major reserves. 
Our analysis revealed 5 key factors to improve the chance of a positive CEESP review: 
(1) A clearly presented analysis with a validated model structure; (2) a submission 
that satisfies the HAS guidelines; (3) a proper justification of all model inputs and 
assumptions; (4) an appropriate comparator; (5) a consideration of the “national fac-
tor”. ConClusions: CEESP appraisal has only recently emerged as a market access 
